Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 12.06% is in line with its 5-year average of 11.92%, around the middle of its 5-year range (4.55%–19.47%).
As of the fiscal period ended Tuesday, June 30, 2026. 27.06% below its 12-month average of 16.54%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.06%.
DEBT TO ASSETS RATIO
12.06%
DEBT TO ASSETS RATIO AVG TTM
16.54%
DEBT TO ASSETS RATIO AVG 3Y
14.69%
DEBT TO ASSETS RATIO AVG 5Y
11.92%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-27.06%
CURRENT VS 3Y AVG
-17.86%
CURRENT VS 5Y AVG
+1.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 596 covered companies
CURRENT VS SECTOR MEDIAN
+11964.56%
vs the sector median at left
Century Therapeutics, Inc.
Market Cap
$257.13M
Debt to Assets Ratio
12.06%
TTM Avg
16.54%
3Y Avg
14.69%
5Y Avg
11.92%
Market Cap
$255.95M
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.91M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$250.09M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.16M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$244.47M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $257.13M | 12.06% | 16.54% | 14.69% | 11.92% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.95M | 0.13% | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.98M | 0.03% | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $259.91M | 0.10% | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $250.09M | 0.03% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | 0.01% | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $246.20M | 0.04% | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $244.47M | 0.00% | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.91M | 0.68% | N/A | N/A | N/A |
Debt/Assets
12.1%
Debt/Equity
0.15
Current Ratio
8.28
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 12.06% |
| 2026-03-31 | 14.71% |
| 2025-12-31 | 19.47% |
| 2025-09-30 | 18.37% |
| 2025-06-30 | 18.08% |
| 2025-03-31 | 16.69% |
| 2024-12-31 | 15.24% |
| 2024-09-30 | 14.05% |
| 2024-06-30 | 13.54% |
| 2024-03-31 | 13.33% |
| 2023-12-31 | 13.36% |
| 2023-09-30 | 11.97% |
| 2023-06-30 | 10.07% |
| 2023-03-31 | 11.41% |
| 2022-12-31 | 10.16% |
| 2022-09-30 | 9.24% |
| 2022-06-30 | 7.75% |
| 2022-03-31 | 4.55% |
| 2021-12-31 | 5.74% |
| 2021-09-30 | 5.38% |
| 2021-06-30 | 5.07% |
| 2021-03-31 | 8.76% |
| 2020-12-31 | 20.19% |
